Vericiguat treatment of heart failure: A systematic review and meta-analysis.
Chronic heart failure
Meta analysis
Randomized controlled trials
Vericiguat
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
16 Dec 2023
16 Dec 2023
Historique:
received:
13
09
2023
revised:
12
11
2023
accepted:
28
11
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
ppublish
Résumé
Heart failure (HF), an end-stage manifestation of various cardiac diseases, poses an enormous economic and health burden on society. Vericiguat may be an effective drug in the treatment of HF. To explore by meta-analysis the efficacy and safety of Vericiguat in treating chronic heart failure. Databases, including PubMed, EMBASE, Web of Science, and Cochrane Library, were searched to collect all published randomized controlled trials (RCTs) on Vericiguat treatment of chronic heart failure from the earliest electronic records to those published in March 2023. Two investigators independently screened the literature according to inclusion and exclusion criteria, evaluated the quality of the studies, and extracted valid data before conducting a meta-analysis using RevMan5.4. Four RCTs with 5919 patients were included, and the meta-analysis showed that treatment with 10 mg Vericiguat reduced the incidence of the primary endpoint (a composite of cardiovascular mortality and first heart-failure-related hospitalization) in patients with chronic heart failure compared to placebo [relative risk (RR) = 0.91, 95% confidence interval (CI): 0.85-0.98, Vericiguat (10 mg) was more effective than placebo in treating patients with chronic heart failure and had a better safety profile.
Sections du résumé
BACKGROUND
BACKGROUND
Heart failure (HF), an end-stage manifestation of various cardiac diseases, poses an enormous economic and health burden on society. Vericiguat may be an effective drug in the treatment of HF.
AIM
OBJECTIVE
To explore by meta-analysis the efficacy and safety of Vericiguat in treating chronic heart failure.
METHODS
METHODS
Databases, including PubMed, EMBASE, Web of Science, and Cochrane Library, were searched to collect all published randomized controlled trials (RCTs) on Vericiguat treatment of chronic heart failure from the earliest electronic records to those published in March 2023. Two investigators independently screened the literature according to inclusion and exclusion criteria, evaluated the quality of the studies, and extracted valid data before conducting a meta-analysis using RevMan5.4.
RESULTS
RESULTS
Four RCTs with 5919 patients were included, and the meta-analysis showed that treatment with 10 mg Vericiguat reduced the incidence of the primary endpoint (a composite of cardiovascular mortality and first heart-failure-related hospitalization) in patients with chronic heart failure compared to placebo [relative risk (RR) = 0.91, 95% confidence interval (CI): 0.85-0.98,
CONCLUSION
CONCLUSIONS
Vericiguat (10 mg) was more effective than placebo in treating patients with chronic heart failure and had a better safety profile.
Identifiants
pubmed: 38130613
doi: 10.12998/wjcc.v11.i35.8330
pmc: PMC10731201
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8330-8342Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.